EXTRACORPOREAL LIFE SUPPORT FOR STATUS ASTHMATICUS

PEDIATRICS ◽  
1994 ◽  
Vol 94 (2) ◽  
pp. 261-261
Author(s):  
Thomas Bell

Purpose of the Study. This report presents the experience with one case of status asthmaticus who failed to respond to mechanical ventilation and was successfully managed with extracorporeal life support (ECLS) using venovenous bypass. The purpose is to inform the practitioner of an additional therapy, potentially of benefit, in management of asthma complicated by treatment-resistant respiratory failure. Methods. Low volume venovenous bypass with extracorporeal life support resolved severe respiratory failure in a 23-year-old female asthmatic over a 22-hour period after failure of 5 hours of mechanical ventilation. Bypass was initiated remotely by an ECLS team using a portable ECLS circuit before the 180-mile transport to the "nearby" center. Details of the technique are presented. Conclusion and Reviewer's Comments. This may be the first instance where asthma was the primary indication for ECLS; other asthmatics have been so treated, but for other complicating conditions like pneumonia and adult respiratory distress syndrome. This report provides a further alternative therapy, even in somewhat remote areas, for asthma-caused respiratory failure.

ASAIO Journal ◽  
2009 ◽  
Vol 55 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Mark E. Mikkelsen ◽  
Y Joseph Woo ◽  
Jeffrey S. Sager ◽  
Barry D. Fuchs ◽  
Jason D. Christie

Author(s):  
Abhimanyu Chandel ◽  
Saloni Patolia ◽  
Kareem Ahmad ◽  
Shambhu Aryal ◽  
A Whitney Brown ◽  
...  

INTRODUCTION Limited evidence exists regarding use of inhaled nitric oxide (iNO) in spontaneously breathing patients. We evaluated the effectiveness of continuous iNO via high-flow nasal cannula (HFNC) in COVID-19 respiratory failure. METHODS We performed a multicenter cohort study of patients with respiratory failure from COVID-19 managed with HFNC. Patients were stratified by administration of iNO via HFNC. Regression analysis was used to compare the need for mechanical ventilation and secondary endpoints including hospital mortality, length of stay, acute kidney injury, need for renal replacement therapy, and need for extracorporeal life support. RESULTS A total of 272 patients were identified and 66 (24.3%) of these patients received iNO via HFNC for a median of 88 h (interquartile range: 44, 135). After 12 h of iNO, supplemental oxygen requirement was unchanged or increased in 52.7% of patients. Twenty-nine (43.9%) patients treated with iNO compared to 79 (38.3%) patients without iNO therapy required endotracheal intubation ( P = .47). After multivariable adjustment, there was no difference in need for mechanical ventilation between groups (odds ratio: 1.53; 95% confidence interval [CI]: 0.74-3.17), however, iNO administration was associated with longer hospital length of stay (incidence rate ratio: 1.41; 95% CI: 1.31-1.51). No difference was found for mortality, acute kidney injury, need for renal replacement therapy, or need for extracorporeal life support. CONCLUSION In patients with COVID-19 respiratory failure, iNO delivered via HFNC did not reduce oxygen requirements in the majority of patients or improve clinical outcomes. Given the observed association with increased length of stay, judicious selection of those likely to benefit from this therapy is warranted.


1994 ◽  
Vol 37 (2) ◽  
pp. 266-274 ◽  
Author(s):  
Harry L. Anderson ◽  
Michael B. Shapiro ◽  
Ralph E. Delius ◽  
Cynthia N. Steimle ◽  
Robin A. Chapman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document